Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2008

Emergent BioSolutions and Ninebio Create Malaysian Joint Venture to Support Biodefense Needs

  • Emergent BioSolutions and Ninebio have formed a joint venture in Malaysia that will focus on creating biologics infrastructure and supplying biodefense countermeasures. The joint venture will be majority owned by Emergent BioSolutions.

    The companies expect to also provide these products and services to certain member countries of the Organisation of the Islamic Conference (OIC) and other nations within Asia. 

    The Malaysian Government owns and funds Ninebio. Through Ninebio, the Government selected Emergent BioSolutions as one of its principal partners to assist as a contract service provider in building vaccine development and manufacturing infrastructure. Besides Emergent BioSolution’s anthrax vaccine, BioThrax®, other medical and complementary products and services will be supplied to the Government of Malaysia.

    “It is our belief that this joint venture will not only expand the use of our anthrax vaccine in this market but will also serve as a platform for joint product development and manufacturing activities,” remarks Fuad El–Hibri, chairman and CEO of Emergent BioSolutions.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »